LYMPHOID NEOPLASIA

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

Christiane Copie-Bergman,[1-3] Peggy Cuillière-Dartigues,[4] Maryse Baia,[3] Josette Briere,[5] Richard Delarue,[6] Danielle Canioni,[7] Gilles Salles,[8] Marie Parrens,[9] Karim Belhadj,[10] Bettina Fabiani,[11] Christian Recher,[12] Tony Petrella,[13] Nicolas Ketterer,[14] Frederic Peyrade,[15] Corinne Haioun,[10] Inga Nagel,[16] Reiner Siebert,[16] Fabrice Jardin,[17] Karen Leroy,[1-3] Jean-Philippe Jais,[18] Herve Tilly,[17] Thierry Jo Molina,[19,*] and Philippe Gaulard[1-3,*]

[1]Assistance Publique–Hôpitaux de Paris, Groupe Henri Mondor–Albert Chenevier, Département de Pathologie, Creteil, France; [2]Universite Paris-Est, Faculté de Médecine, Unité Mixte de Recherche Scientifique 955, Créteil, France; [3]INSERM, Unité 955, Creteil, France; [4]Institut Gustave Roussy, Villejuif, France; [5]Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Department of Pathology, Institut Universitaire d'Hématologie, Paris, France; [6]Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Department of Hematology, Paris, France; [7]Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Department of Pathology, Université Paris Descartes, Paris, France; [8]Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Service d'Hématologie, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Lyon, France; [9]Centre Hospitalier Universitaire Bordeaux, Université de Bordeaux, EA2406, Bordeaux, France; [10]Assistance Publique–Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, Unité Lymphoïde, Créteil, France; [11]Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Antoine, Department of Pathology, Paris, France; [12]Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France; [13]Department of Pathology, Hôpital Maisonneuve-Rosemont, Montreal, Canada; [14]Pluridisciplinary Center for Oncology, University Hospital–Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; [15]Centre de Lutte Contre le Cancer de Nice, Nice, France; [16]Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany; [17]Centre Henri Becquerel and INSERM Unité 918, Institut de Recherche et d'Innovation Biomédicale, Rouen, France; [18]Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Department of Biostatistics, Paris, France; and [19]Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Department of Pathology, Université Paris Descartes, EA 7324, Paris, France

Key Points

- *MYC-IG* translocation partner gene is a negative predictor of survival in DLBCL patients.

Diffuse large B-cell lymphoma (DLBCL) with *MYC* rearrangement (*MYC*-R) carries an unfavorable outcome. We explored the prognostic value of the *MYC* translocation partner gene in a series of *MYC*-R de novo DLBCL patients enrolled in first-line prospective clinical trials (Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association) and treated with rituximab-anthracycline–based chemotherapy. A total of 774 DLBCL cases characterized for cell of origin by the Hans classifier were analyzed using fluorescence in situ hybridization with *BCL2*, *BCL6*, *MYC*, immunoglobulin (*IG*)*K*, and *IGL* break-apart and *IGH/MYC*, *IGK/MYC*, and *IGL/MYC* fusion probes. *MYC*-R was observed in 51/574 (8.9%) evaluable DLBCL cases. *MYC*-R cases were predominantly of the germinal center B-cell–like subtype 37/51 (74%) with no distinctive morphologic and phenotypic features. Nineteen cases were *MYC* single-hit and 32 cases were *MYC* double-hit (*MYC* plus *BCL2* and/or *BCL6*) DLBCL. *MYC* translocation partner was an *IG* gene in 24 cases (*MYC-IG*) and a non-*IG* gene (*MYC*-non-*IG*) in 26 of 50 evaluable cases. Noteworthy, *MYC-IG* patients had shorter overall survival (OS) (*P* = .0002) compared with *MYC*-negative patients, whereas no survival difference was observed between *MYC*-non-*IG* and *MYC*-negative patients. In multivariate analyses, *MYC-IG* predicted poor progression-free survival (*P* = .0051) and OS (*P* = .0006) independently from the International Prognostic Index and the Hans classifier. In conclusion, we show in this prospective randomized trial that the adverse prognostic impact of *MYC*-R is correlated to the *MYC-IG* translocation partner gene in DLBCL patients treated with immunochemotherapy. These results may have an important impact on the clinical management of DLBCL patients with *MYC*-R who should be routinely characterized according to *MYC* partner gene. These trials are individually registered at www.clinicaltrials.gov as #NCT00144807, #NCT01087424, #NCT00169143, #NCT00144755, #NCT00140660, #NCT00140595, and #NCT00135499. (*Blood*. 2015;126(22):2466-2474)

Introduction

MYC is an oncogene involved in the pathogenesis of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).[1] MYC transcription factor plays a dual role as gene amplifier but also downregulates tumor cell proliferation by regulating the P53 apoptotic pathway.[2,3] According to published studies, *MYC* rearrangement (*MYC*-R) is observed in 7% to 21% of DLBCL cases.[4-15] *MYC* break may occur de novo as a sole genetic event or in combination with *BCL2* and/or *BCL6* translocations defining

---

so-called "double-hit" (DHL) or "triple-hit" lymphomas (THL).[16] Most *MYC*-R DLBCL have a germinal center B-cell–like (GCB) phenotype as defined by the Hans immunohistochemical classifier.[16,17] In contrast to BL where *MYC* is classically translocated within the immunoglobulin (*IG*) loci, either the *IG* heavy chain gene (*IGH*) or more rarely the Ig light chain genes κ (*IGK*) or λ (*IGL*), up to half of *MYC*-R DLBCL involve non-*IG* translocation partner genes including *BCL6*, *PAX5*, *BCL11A*, or *IKAROS*.[17-21]

When considering the clinical relevance of *MYC*-R in DLBCL, there remain several unresolved issues. First, many groups have focused on the prognostic value of *MYC* gene deregulation in a variety of "aggressive" B-cell lymphomas with controversial results. In DLBCL, most studies have reported *MYC*-R as a strong adverse prognostic factor,[4-10,22] whereas others failed to demonstrate any significant impact of *MYC*-R alone on survival.[11,12,19,20] Secondly, DHL have been reported to have an extremely poor prognosis, but most studies were based on the retrospective analysis of patients presenting with very aggressive clinical features, thereby precluding their inclusion in any prospective clinical trials.[16,17,23-28] Finally, the potential role of the *MYC* translocation partner gene has been addressed in a few recent studies. Interestingly, although heterogeneous in terms of histologies and therapy, they suggested a possible prognostic impact of an *IG* partner gene.[17,19,20]

This prompted us to investigate the prognostic value of the *MYC* translocation partner gene (*IG* vs non-*IG*) in de novo DLBCL patients enrolled in first-line prospective Groupe d'Etudes des Lymphomes de l'Adulte (GELA)/Lymphoma Study Association (LYSA) clinical trials, and treated with rituximab and anthracycline-based chemotherapy. In this study, we also focused on the clinical relevance of *MYC*-R–associated parameters such as single-hit (SH) or double-hit (DH) status in this clinical context.

Patients and methods

Patient selection

A total of 1696 patients with previously untreated de novo CD20[+] DLBCL were enrolled in the GELA/LYSA LNH01-5B and LNH03-B clinical trials. LNH01-5B was a randomized trial initiated in 2001 that included de novo CD20[+] DLBCL patients (age-adjusted International Prognosis Index [aaIPI] = 2 to 3, age 60 to 65 years) randomly assigned to treatment with *R*-CHOP or rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (*R*-ACVBP). The LNH03-B trial initiated in 2003 was dedicated to patients with de novo previously untreated CD20[+] DLBCL. Patients were stratified according to age and aaIPI, and were assigned to the following randomized trials: LNH03-1B (aaIPI = 0, <60 years), LNH03-2B (aaIPI = 1, <60 years), LNH03-3B and 39B (aaIPI = 2 to 3, <60 years), LNH03-6B (aaIPI = 0 to 3, age 60 to 80 years), and LNH03-7B (>80 years). Details regarding the design and data management of the LNH03-2B, 03-3B, and 03-7B trials have been published.[29-32] Treatments included *R*-CHOP21/14 (03-6B, 03-2B, 01-5B), *R*-mini-CHOP21 (03-7B), and *R*-ACVBP or ACVBP (03-1B and 03-3B, 03-39B) regimens. The trials are individually registered at clinicaltrials.gov as noted previously. For the purpose of the current study, only patients with DLBCL treated with rituximab-associated chemotherapy were selected. These studies complied with all provisions of the Declaration of Helsinki and were conducted in accordance with good clinical practice guidelines. All patients gave written informed consent to participate and to provide tissue material for biological studies.

Morphology

Tumor samples from CD20[+] DLBCL patients enrolled in the trials were centrally reviewed by at least two hematopathologists from LYSA to confirm the diagnosis of CD20-positive DLBCL according to the World Health Organization classification.[1] Tissue microarrays (TMA) containing 3 representative 0.6-mm cores of routinely processed tissues from DLBCL cases were prepared (Beecher Instruments, Silver Spring, MD). Only patients with large tumor samples were selected for TMA (excluding needle biopsy). Among patients with available tissue blocks, 854 were subjected to TMA. The quality of each tissue core was evaluated for morphology using hematoxylin and eosin staining and for the percentage of CD20[+] tumor cells. Only tissue cores with more than 50% CD20[+] tumor cells were considered evaluable for fluorescence in situ hybridization (FISH) and immunohistochemical studies. Consequently, the eligible population included 774 patients with a pre-analytical validation of TMA cores.

Immunohistochemistry

Paraffin tissue sections from TMA blocks (3 μm thick) were subjected to antigen retrieval and immunostained on a BenchMark Ultra automated stainer (Roche Ventana, Tucson, AZ) for CD20, CD5, CD10, BCL6, and MUM1 as previously described.[33] In addition, Mib1 (Ki67), BCL2 (clone 124; Dako Cytomation, Glostrup Denmark) and MYC (Epitomics, Burlingame, CA) were performed on full slides of *MYC*-R DLBCL. The cell of origin classification was based on the Hans algorithm.[34] A detailed additional pathological review of all *MYC*-R cases was performed by 4 expert hematopathologists (C.C.B., T.J.M., J.B., and P.G.) with additional immunostainings for Ki67, BCL2, and MYC, and with the knowledge of FISH results to search for any specific pathological features (ie, cytological appearance, starry sky pattern, Ki67 proliferative index, and level of MYC protein expression).

Interphase FISH analysis

FISH analysis was performed on 3 μm TMA tissue sections using break-apart FISH DNA probes for c*MYC*/8q24, *BCL2*/18q21, and *BCL6*/3q27 (probes Y5410, Y5407, and Y5408; Dako A/S) as previously described.[35] All cases with *MYC*-R were further analyzed using Vysis LSI *IGH/MYC/CEP* 8 Tri-Color Dual Fusion Probes (Abbott Laboratories, Chicago, IL) and *IGK* and *IGL* break-apart FISH DNA probes (Y5416 and Y5412; Dako A/S). In cases where FISH with break-apart probes suggested breakpoints affecting the *MYC* locus as well as one of the *IG* light-chain loci, *IGK* or *IGL*, interphase FISH was performed using *IGK-MYC* and *IGL-MYC* double-color fusion assays.[4,36] Slides were evaluated under a fluorescence microscope (Zeiss, Göttingen, Germany) equipped with appropriate filter sets.

Statistical analysis

Patients' characteristics and response rates were compared using the χ^2 or Fisher's exact tests (depending on the number of observations) for categorical parameters and the Mann–Whitney test for continuous parameters. Overall survival (OS) was measured from date of randomization to death from any cause and progression-free survival (PFS) from the date of randomization to the date of disease progression, relapse, or death from any cause. Survival analyses were performed using the log-rank test and expressed as Kaplan–Meier plots with appropriate 95% CIs. Multivariate analyses were performed with a Cox proportional hazards regression model. Differences between the results of comparative tests were considered significant if the 2-sided *P* value was < .05. Statistical analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC).

Results

Clinical characteristics and outcome of the global population

Of the 774 DLBCL patients treated by *R*-chemo and with evaluable TMA tissue cores, 574 (74%) had interpretable FISH signals using a *MYC* break-apart probe and constituted our study population (Figure 1). The clinical characteristics of the patients are listed in Table 1. The median age was 62 years (range, 18 to 93 years). The median follow-up was 43 months (range, 0.3 to 83.2 months). The response rate at the end

Figure 1. Flow-chart of LNH03-B and LNH01-5B cohort, case selection, and FISH results. *BCL2-R*, DLBCL with *BCL2* gene rearrangement; *BCL6-R*, DLBCL with *BCL6* gene rearrangement; *MYC-R*, DLBCL with *MYC* gene rearrangement; *MYC-IG*, *MYC* gene rearrangement with *IG* partner gene; *MYC-non-IG*, *MYC* gene rearrangement with non-*IG* partner gene.

of the treatment was 80.5% (complete remission/unconfirmed complete remission). The 5-year PFS for the 574 patients was 64% and the 5-year OS was 72.3%. The majority of the patients (63.2%) received *R*-CHOP (319) or *R*-mini-CHOP (44), and 211 patients (36.8%) received *R*-ACVBP. The clinical features of the 574 patients of this study were similar to those of the entire cohort of patients (n = 1696) included in the LNH-01-5B and LNH03 trials (data not shown).

FISH results

BCL2/18q21, B*CL6*/3q27, and *MYC*/8q24 gene rearrangements were observed in 21.2% (122/574), 27.4% (157/573), and 8.9% (51/574) of the cases, respectively (Figure 1). Fifteen cases harbored both *BCL2* and *BCL6* gene rearrangements (15/573 = 2.6%).

MYC-R cases were subdivided into *MYC-SH* (19 cases) when there was no concomitant rearrangement of both *BCL2* and *BCL6,* and *MYC-DH* (32 cases) when concurrent *BCL2* and/or *BCL6* breakpoints were observed. For simplification, the term "double-hit" was used for all cases with *MYC-R* and additional breakpoints, including triple-hit cases. In total, *MYC-DH* included 19 *MYC/BCL2*, 7 *MYC/BCL6*, and 6 *MYC/BCL2/BCL6* cases.

MYC-R tumor samples were evaluable for *MYC Ig* partner genes using *MYC/IgH/CEN8* fusion probe, and *IGK* and *IGL* break-apart probes: 23 cases showed *MYC/IGH* fusion signals and 5 cases *IGK* (n = 3) or *IGL* (n = 2) breaks. In order to demonstrate whether these *IGK* or *IGL* were fused to the *MYC* gene, 4 of these 5 cases with sufficient material available were further evaluated with *MYC-IGK* or *MYC-IGL* fusion probes. Only 1 of these 4 cases with *IGK* or *IGL* breaks displayed *MYC-IGL* fusion signals. Therefore, the other 3 were assigned to the non-*IG-MYC* group.

Altogether, among the 50 *MYC-R* DLBCL evaluable for *MYC-IG* partner gene, *MYC* translocation partner genes involved *IG* loci in 24 cases (23 *IGH* and 1 *IGL*) and were called *MYC-IG,* whereas the partner gene was a non-*IG* gene in 26 cases (*MYC-non-IG*).

Pathological features of *MYC-R* DLBCL cases

To search for potential peculiar morphologic and phenotypic features, the 51 *MYC-R* DLBCL cases were re-reviewed with additional immunostainings for Ki67, MYC, and BCL2 performed on full slides, and the FISH results were as follows: 47 cases were confirmed as DLBCL not otherwise specified (DLBCL NOS) and included 43 centroblastic

variants and 4 immunoblastic variants of DLBCL (3 *MYC-IG* and 1 *MYC-non-IG*), 2 DLBCL NOS were associated with a minor focal follicular lymphoma component, whereas only 4 cases could retrospectively be considered as having some features of B-cell lymphoma, unclassifiable, or intermediate between DLBCL and BL (BCLu) (Table 2). Among the 51 cases, only a minority showed high numbers of apoptotic bodies (8/49 = 16.3%), or mitosis (13/49 = 26.5%) and a starry sky pattern (7/49 = 14.3%). No significant differences based on these morphologic criteria were observed between SH/DH or *IG*/non-*IG* subgroups.

According to the Hans algorithm, the majority of *MYC-R* cases were of the GCB subtype (74%). *MYC-SH* lymphomas included 12 GCB and 7 non-GCB cases. *MYC-DH* lymphomas included 25 GCB (18 *MYC/BCL2*, 6 THL, and 1 *MYC/BCL6*) and 6 non-GCB cases (6 *MYC/BCL6*). A proliferative index ≥80% evaluated with Ki67 immunostaining was significantly more frequent in *MYC-SH* compared with *MYC-DH* tumors (78.9% vs 50.0%; *P* = .043).

BCL2 protein (50% or 70% threshold) was expressed in 37/50 (74%) of *MYC-R* evaluable cases. High BCL2 expression (>50% or 70%) was significantly more frequent in *MYC-DH* compared with *MYC-SH* DLBCL (83.9% vs 57.9%; *P* = .042), whereas no significant differences were noted between *MYC-IG* and *MYC-non-IG* subgroups (64.3% vs 86.4%; *P* = .077).

MYC protein expression in virtually all tumor cells (≥90%) was observed in 23/50 (46%) of evaluable cases. No significant difference was observed between the SH and DH subgroups (57.9% vs 38.7%; *P* = .186), whereas high MYC protein expression was significantly more frequent in the *MYC-Ig* subgroup compared with *MYC-non-IG* DLBCL (62.5% vs 32%; *P* = .032).

Clinical features of *MYC-R* DLBCL patients

Comparison of the clinical characteristics of *MYC-R* vs *MYC*-negative, *MYC-SH* vs *MYC-DH*, *MYC-IG* vs *MYC-non-IG* DLBCL patients are presented in Table 1. Compared with *MYC*-negative DLBCL patients, *MYC-R* patients presented with higher International Prognosis Index (IPI) score (*P* < .001), aaIPI (*P* = .015), Ann Arbor stage (*P* = .005), number of extranodal sites (*P* = .004), and frequency of bone marrow involvement (*P* = .011). There were no significant clinical and biological differences between *MYC-SH* and *MYC-DH* subgroups of patients. *MYC-IG* compared with *MYC-non-IG* patients were significantly older (median age, 69 vs 60.5 years; *P* = .027) and presented a higher number of extranodal sites involvement (*P* = .042), whereas conversely, *MYC-non-IG* patients showed a higher frequency of B symptoms (*P* = .019).

Patient outcome

By univariate analysis, high IPI and non-GCB subtype were significantly associated with shorter PFS and OS (IPI: PFS and OS, *P* < .0001) (Cell of origin: PFS, *P* = .0001; OS, *P* = .0004). *BCL2* and *BCL6* gene alterations did not significantly predict survival (PFS and OS) (see supplemental Table 1A, available on the *Blood* Web site).

MYC-R, *MYC-SH*, and *MYC-DH* were associated with shorter OS in the global population (*P* = .0058; *P* = .0339; and *P* = .0457, respectively) (Figure 2; supplemental Table 1A). *MYC-R*, *MYC-SH*, and *MYC-DH* were associated with shorter PFS and OS in GCB DLBCL (PFS: *P* = .0014, *P* = .0269, and *P* = .0078, respectively; OS: *P* = .0001, *P* = .0153, and *P* = .0007, respectively), a finding that did not reach the level of significance in the non-GCB subtype (supplemental Figure 1; supplemental Table 1B). Interestingly, all but one GCB *MYC-DH* consisted of *MYC/BCL2* cases (18 MYC/BCL2,

Table 1. Clinical features of *MYC*-R vs *MYC*-neg, *MYC*-SH vs *MYC*-DH, and *MYC*-IG vs *MYC*-non-*IG* partner gene

	All patients (n = 574) n (%)	MYC-neg (n = 523) n (%)	MYC-R (n = 51) n (%)	P	MYC-SH (n = 19) n (%)	MYC-DH (n = 32) n (%)	P	MYC-IG (n = 24) n (%)	MYC-non-IG (n = 26) n (%)	P
Median age (range), y	62 (18-93)	62 (18-93)	64 (29-84)	.213	65 (29-84)	62.5 (35-84)	.546	69 (29-84)	60.5 (32-84)	.027
Sex				.285			.789			.817
Male	308 (53.7)	277 (53.0)	31 (60.8)		12 (63.2)	19 (59.4)		14 (58.3)	16 (61.5)	
Female	266 (46.3)	246 (47.0)	20 (39.2)		7 (36.8)	13 (40.6)		10 (41.7)	10 (38.5)	
IPI score				< .001			.077			.324
0	50 (8.7)	47 (9.0)	3 (5.9)		2 (10.5)	1 (3.1)		0 (0.0)	3 (11.5)	
1	119 (20.7)	115 (22.0)	4 (7.8)		1 (5.3)	3 (9.4)		1 (4.2)	3 (11.5)	
2	143 (24.9)	133 (25.4)	10 (19.6)		7 (36.8)	3 (9.4)		5 (20.8)	5 (19.2)	
3	143 (24.9)	124 (23.7)	19 (37.3)		3 (15.8)	16 (50.0)		8 (33.3)	10 (38.5)	
4	91 (15.9)	85 (16.3)	6 (11.8)		2 (10.5)	4 (12.5)		4 (16.7)	2 (7.7)	
5	28 (4.9)	19 (3.6)	9 (17.6)		4 (21.1)	5 (15.6)		6 (25.0)	3 (11.5)	
Age adjusted IPI				.015			.237			.338
0	69 (12.0)	66 (12.6)	3 (5.9)		2 (10.5)	1 (3.1)		0 (0.0)	3 (11.5)	
1	246 (42.9)	230 (44.0)	16 (31.4)		8 (42.1)	8 (25.0)		8 (33.3)	8 (30.8)	
2	205 (35.7)	183 (35.0)	22 (43.1)		5 (26.3)	17 (53.1)		10 (41.7)	11 (42.3)	
3	54 (9.4)	44 (8.4)	10 (19.6)		4 (21.1)	6 (18.8)		6 (25.0)	4 (15.4)	
Ann Arbor stage				.005			.268			.187
I-II	152 (26.5)	147 (28.1)	5 (9.8)		3 (15.8)	2 (6.3)		1 (4.2)	4 (15.4)	
III-IV	422 (73.5)	376 (71.9)	46 (90.2)		16 (84.2)	30 (93.8)		23 (95.8)	22 (84.6)	
Performance status (ECOG)				.224			.860			.691
0-1	499 (86.9)	458 (87.5)	41 (80.4)		15 (79.0)	26 (81.2)		18 (75.0)	21 (84.6)	
≥2	75 (13.0)	65 (12.4)	10 (19.6)		4 (21.0)	6 (18.8)		6 (25.0)	4 (15.4)	
LDH > normal	320 (55.8)	286 (54.8)	34 (66.7)	.103	10 (52.6)	24 (75.0)	.101	17 (70.8)	16 (61.5)	.488
Extranodal site >1	209 (36.4)	181 (34.6)	28 (54.9)	.004	10 (52.6)	18 (56.3)	.802	17 (70.8)	11 (42.3)	.042
Bone marrow involvement	88 (16.6)	74 (15.3)	14 (29.7)	.011	5 (29.4)	9 (30.0)	.966	9 (40.9)	5 (20.8)	.139
Mass >10 cm	83 (15.3)	77 (15.6)	6 (12.8)	.612	1 (5.3)	5 (17.9)	.204	5 (20.8)	1 (4.5)	.101
B symptoms	183 (31.9)	169 (32.4)	14 (27.5)	.472	3 (15.8)	11 (34.4)	.150	3 (12.5)	11 (42.3)	.019
β 2 microglobulin (≥3 mg/L)	160 (33.8)	141 (33.0)	19 (40.4)	.308	6 (33.3)	13 (44.8)	.435	11 (45.8)	8 (34.8)	.440
Albumin (g/L) ≤35 g/L	123 (24.6)	110 (24.2)	13 (28.3)	.540	5 (31.3)	8 (26.7)	.742	9 (39.1)	4 (18.2)	.121
LNH trials				—			—			—
LNH03-1B	51 (8.9)	48 (9.2)	3 (5.9)		2 (10.5)	1 (3.1)		0 (0.0)	3 (11.5)	
LNH03-2B	139 (24.2)	129 (24.7)	10 (19.6)		5 (26.3)	5 (15.6)		4 (16.7)	6 (23.1)	
LNH03-3B	47 (8.2)	44 (8.4)	3 (5.9)		0 (0)	3 (9.4)		1 (4.2)	2 (7.7)	
LNH03-39B	22 (3.8)	20 (3.8)	2 (3.9)		0 (0)	2 (6.3)		1 (4.2)	1 (3.8)	
LNH03-6B	240 (41.8)	216 (41.3)	24 (47.1)		9 (47.4)	15 (46.9)		15 (62.5)	8 (30.8)	
LNH03-7B	44 (7.7)	39 (7.5)	5 (9.8)		3 (15.8)	2 (6.3)		3 (12.5)	2 (7.7)	
LNH01-5B	31 (5.4)	27 (5.2)	4 (7.8)		0 (0)	4 (12.5)		0 (0.0)	4 (15.4)	
Arm of treatment				—			—			—
R-ACVBP	189 (32.9)	176 (33.7)	13 (25.5)		2 (10.5)	11 (34.4)		2 (8.3)	11 (42.3)	
R-ACVBP+ASCT	22 (3.8)	20 (3.8)	2 (3.9)		0 (0)	2 (6.3)		1 (4.2)	1 (3.8)	
R-CHOP21	200 (34.8)	179 (34.2)	21 (41.2)		9 (47.4)	12 (37.5)		10 (41.7)	11 (42.3)	
R-CHOP14	119 (20.7)	109 (20.8)	10 (19.6)		5 (26.3)	5 (15.6)		8 (33.3)	1 (3.8)	
R-mini-CHOP21	44 (7.7)	39 (7.5)	5 (9.8)		3 (15.8)	2 (6.3)		3 (12.5)	2 (7.7)	
Arm of treatment				—			—			—
R-ACVBP	211 (36.8)	196 (37.5)	15 (29.4)		2 (10.5)	13 (40.6)		3 (12.5)	12 (46.2)	
R-CHOP	363 (63.2)	327 (62.5)	36 (70.6)		17 (89.5)	19 (59.4)		21 (87.5)	14 (53.8)	

ECOG, Eastern Cooperative Oncology Group; LNH, non-Hodgkin lymphoma; *MYC*-neg, DLBCL without *MYC* gene rearrangement.

6 THL, and 1 *MYC/BCL6*), whereas all non-GCB MYC-DH were *MYC/BCL6* cases.

The outcome of *DH-BCL2* (including THL) (n = 25) and *DH-BCL6* (n = 7) were compared. A trend toward a lower PFS and OS for *DH-BCL2* was noted (supplemental Figure 3), which did not reach statistical significance within the limits of the number of cases in each subgroup (PFS: *P* = .1966; OS: *P* = .2839).

When considering the *MYC* translocation partner gene, *MYC-IG* patients had a significantly shorter PFS (*P* = .0023) and OS (*P* = .0002) when compared with *MYC*-negative DLBCL patients, whereas no significant differences were observed between *MYC*-non-*IG* and *MYC* negative patients on PFS (*P* = .9661) and OS (*P* = .6526) (Figure 3; supplemental Table 1A). A similar impact of *MYC-IG* on OS

was observed in the *MYC*-SH (*P* = .0175) and *MYC*-DH (*P* = .0023) subgroups. *MYC-IG* translocations had an adverse prognostic effect on PFS (*P* < .0001) and OS (*P* < .0001) in GCB DLBCL, which did not reach statistical significance in the non-GCB subtype (supplemental Figure 2; supplemental Table 1B). A similar poor impact of *MYC-IG* partner gene on OS was observed in GCB SH/DH DLBCL subgroups (supplemental Figure 2; supplemental Table 1B). No interaction was found between *MYC*-R and treatment regimen (*R*-CHOP vs *R*-ACVBP) (data not shown).

In a multivariate analysis incorporating IPI, Hans score, and *MYC*-R, *MYC*-R remained statistically significant on OS (*P* = .0089) (supplemental Table 2A). In a multivariate analysis incorporating IPI, Hans score, and *MYC*-SH or *MYC*-DH status, only *MYC*-SH remained

Table 2. Pathological features of the 51 MYC-R DLBCL cases according to the SH/DH or IG/non-IG status

	MYC-R (n = 51) n (%)	MYC-SH (n = 19) n (%)	MYC-DH (n = 32) n (%)	P (MYC-SH vs MYC-DH)	MYC-IG (n = 24) n (%)	MYC-non-IG (n = 26) n (%)	P (MYC-IG vs MYC-non-IG)
Histologic subtype				.452			.221
DLBCL NOS (*)	47 (92)	18 (94.7)	29 (90)		21 (87.5)	25 (96.1)	
Consistent with BCLu	4 (7.8)	1 (5.3)	3 (9.4)		3 (12.5)	1 (3.8)	
Apoptotic bodies (n = 49)				.0935			1.0
0-2	41 (83.7)	16 (84.2)	25 (83.3)		20 (83.3)	20 (83.3)	
3	8 (16.3)	3 (15.8)	5 (16.7)		4 (16.7)	4 (16.7)	
Starry sky pattern (n = 49)				.550			.683
0-2	42 (85.7)	17 (89.5)	25 (83.3)		21 (87.5)	20 (83.3)	
3	7 (14.3)	2 (10.5)	5 (16.7)		3 (12.5)	4 (16.7)	
Mitosis (n = 49)				.193			.745
0-2	36 (73.5)	12 (63.2)	24 (80.0)		18 (75.0)	17 (70.8)	
3	13 (26.5)	7 (36.8)	6 (20.0)		6 (25.0)	7 (29.2)	
Hans score (n = 50)				.171			.682
GCB	37 (74.0)	12 (63.2)	25 (80.6)		17 (70.8)	19 (76.0)	
Non-GCB	13 (26.0)	7 (36.8)	6 (19.4)		7 (29.2)	6 (24.0)	
Ki67 ≥80% (n = 49)	30 (61.2)	15 (78.9)	15 (50.0)	.043	15 (65.2)	14 (56.0)	.514
BCL2 protein (>50% or 70%) (n = 50)	37 (74.0)	11 (57.9)	26 (83.9)	.042	18 (64.3)	19 (86.4)	.077
MYC protein ≥90% (n = 50)	23 (46)	11 (57.9)	12 (38.7)	.186	15 (62.5)	8 (32)	.032
MYC partner gene†				.038			<.001
IG (IGH, K, L)	24 (48)	12 (63.2)	12 (38.7)		24 (100.0)	0 (0)	
Non-IG	26 (52)	7 (36.8)	19 (61.3)		0 (0)	26 (100)	

BCLu: B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL.

*Including 2 cases with a minor follicular lymphoma component.

†1 case was not evaluable for MYC partner gene.

an independent prognostic factor on PFS ($P = .0482$) and OS ($P = .0139$) in addition to IPI and Hans score (supplemental Table 2B). However, when excluding MYC/BCL6 DH cases from the MYC-DH group, MYC/BCL2 DH status (including THL) had an independent poor prognostic impact on both PFS ($P = .027$) and OS ($P = .0055$) (supplemental Table 2C).

When considering the MYC translocation partner gene, MYC-IG predicted a poor PFS ($P = .0051$) and OS ($P = .0006$) in addition to IPI and the Hans score (supplemental Table 2D). Because the median age of MYC-IG patients was almost a decade older than MYC-non-IG patients, age was evaluated by multivariate analysis and remained an independent prognostic factor (data not shown).

Discussion

To the best of our knowledge, this is the first study addressing the impact of the MYC partner gene in a large series of unselected patients with de novo DLBCL and treated with rituximab-anthracycline–based chemotherapy in the setting of prospective clinical trials. In this series of 574 DLBCL patients, we show that MYC-IG had a significant negative impact on outcome (PFS and OS), whereas no significant difference in PFS and OS was observed between MYC-non-IG and MYC-negative DLBCL. These results may have an important impact on the clinical management of DLBCL patients with MYC-R who should be characterized according to MYC partner gene, because non-IG MYC partner genes appear to have little influence on survival.

The prognostic impact of the MYC partner gene in DLBCL associated with MYC-R is currently a major issue but has remained controversial.[37] Indeed, this issue has been discussed in only 3 previous studies that included B-cell lymphoma patients with heterogeneous lymphoma entities, patients at diagnosis and at relapse,

and/or patients treated before the era of rituximab resulting in discrepant results. Johnson et al were the first to point out the potential relevance of IG as a MYC partner in a retrospective series of 54 patients with DH MYC/BCL2 BCLs diagnosed between 1991 and 2007, selected on the basis of availability of karyotypic analysis.[17] Histologies were variable including only 17 de novo DLBCL patients (n = 17) and the prognosis impact of the MYC partner gene could be evaluated in 40 patients including 11 patients receiving rituximab-based chemotherapy. The study by Pedersen et al was based on a prospective cohort comprising all patients diagnosed with DLBCL or BCLu in a single institution between 2009 and 2011.[20] Histopathological subtypes included de novo DLBCL (n = 162), transformed DLBCL (n = 65), and relapse (n = 25). Treatment regimens were variable with 14% of patients not receiving rituximab. MYC translocation was observed in 51 cases but, unexpectedly, showed no correlation with OS, whereas MYC translocation with an IG partner gene was reported to correlate with a worse prognosis. However, in addition to the above limitations, the data presented in this study were also controversial because the authors considered 21 cases with concurrent MYC and IGK or IGL rearrangements detected using break-apart probes as MYC-IG cases, which most likely represents an overstatement since these cases were not investigated for MYC-IGK or MYC-IGL fusions with appropriate probes. Indeed, in our study, among the 4 cases showing concurrent MYC and IGK or IGL light chain rearrangements using break-apart probes, only 1 proved to be a "real" MYC-IG case with the MYC-IGL fusion probe and the remaining cases were assigned to the non-IG subgroup. Finally, Aukema et al focused on 80 MYC-R B-cell lymphomas of various histopathological subtypes and found no significant difference between MYC-SH vs MYC-DH and MYC-IG vs MYC-non-IG lymphoma subgroups regarding the molecular cytogenetic, array-CGH, mutational, gene-expression profiles, and survival.[38] Overall, it can be speculated that the discrepancies observed between the above mentioned reports are related to the heterogeneity of the populations

Figure 2. Univariate analysis of *MYC*-R for OS. (A) The global population, (B) SH, and (C) subgroups of DLBCL patients.

studied (which comprised various histopathological subtypes), making the results difficult to compare.

We observed an overall incidence of *MYC*-R of 8.9%, which is consistent with the literature by using a commercially available probe that covers most breakpoints commonly involved in *MYC* translocations, and similar to the majority of previous published series.[10,17-19,34,39,40] We corroborate previous reports on the adverse prognostic impact of *MYC*-R in DLBCL, which remained an independent prognostic factor for OS in multivariate analysis incorporating IPI and the Hans score.[4-10,14,22] However, we show that this prognostic impact is related to the *MYC-Ig* partner gene.

In this prospective study of de novo unselected DLBCL, the incidence of *MYC*-SH was 3.3% (19/574) and *MYC*-DH was 5.6% (32/574). In univariate analysis, *MYC*-SH and *MYC*-DH were associated with poor OS, but in multivariate analysis, only *MYC*-SH retained a poor prognostic significance on OS. These results might appear in contrast to a previous study by Hummel et al reporting "*MYC*-simple" aggressive B-cell lymphomas including BLs, as having a favorable outcome.[4] However, our series differs from the previous study as we excluded BLs. In addition, "*MYC*-simple" according to Hummel et al was defined by the presence of *MYC-IG* fusions, a low chromosomal complexity score using array-based comparative genomic hybridization and absence of *BCL2* or *BCL6* breaks. The FISH approach adopted in our study explored 3 major oncogenic loci (*BCL2, BCL6,* and *MYC*) but did not address the

genetic complexity of the tumor, and therefore does not preclude the presence of additional cytogenetic abnormalities.

Concerning *MYC*-DH, the absence of prognosis significance by multivariate analysis may appear unexpected as the majority of published reports describe DHL as highly aggressive tumors with poor outcome and resistance to conventional chemotherapy.[16,17,23-28,41] Although further studies are needed to understand such differences, it is noteworthy that *MYC*-DH patients in our series probably differ from DHL patients of previous reports because we included only patients with newly diagnosed DLBCL enrolled in controlled clinical trials in contrast to all aforementioned studies, which were a retrospective series of aggressive BCLs. In addition, patients enrolled in clinical trials are usually biased toward more healthy patients. Moreover, most studies did not perform FISH for *BCL6* and may have missed *MYC/BCL6* DHL and THL. Interestingly, when excluding the *MYC/BCL6* tumors from the *MYC*-DH group in the multivariate analysis, *MYC/BCL2* DH status retained its independent poor prognosis significance on both PFS and OS, suggesting that the poor prognosis of DHL is most likely related to *MYC/BCL2* DHs. In this respect, when comparing the outcome of *MYC/BCL2* and *MYC/BCL6* DHL patients, we observed a trend toward a worse PFS and OS for *MYC/BCL2* patients, although this remained nonsignificant probably due to the limited number of cases. International efforts with large cohorts of de novo DLBCL patients enrolled in clinical trials would be

Figure 3. Univariate analysis of *MYC-IG* for OS. (A) The global population, (B) SH, and (C) DH subgroups of DLBCL patients compared with *MYC*-non-*IG* and *MYC*-negative DLBCL patients.

needed to explore this issue. Altogether, de novo DHL DLBCL probably represents a heterogeneous group of diseases with variable outcomes, including patients with aggressive presentation and a very poor outcome, and a group of DLBCL NOS without major distinct clinical and pathological features.

The pathological review of *MYC*-R DLBCL showed that most cases were GCB DLBCL (74%) in keeping with previous studies.[8,9,16,17] Interestingly, the features usually believed to be associated with aggressiveness as apoptotic bodies, starry sky pattern, and mitosis were not prominent. The proliferative index evaluated with Ki67 immunostaining was variable and found to be ≤80% in 40% of the cases, indicating that immunostaining for Ki67 is not relevant to prescreen for *MYC*-R DLBCL as already reported.[14,42] BCL2 overexpression was significantly more frequent in *MYC*-DH than *MYC*-SH patients, which may be explained by the large number of *MYC/BCL2* DHL in this series. MYC protein expression in virtually all tumor cells (≥90%) was observed only in 46% of *MYC*-R cases, suggesting that immunostaining for MYC may not be an efficient surrogate to detect *MYC*-R DLBCL. Altogether, there were no clear pathological features in routine practice that may indicate that a DLBCL may harbor *MYC*-R.

The biological basis for the dismal outcome of *MYC-IG* DLBCL patients needs to be clarified. We show that a high level of MYC protein expression (≥90%) correlated with the *MYC-IG* subgroup, in agreement with a higher level of *MYC* transcripts in *MYC-IG* cases compared with *MYC*-non-*IG* cases observed in previous reports.[21,38] These findings suggest that a full "*MYC*-program" may not be reached with a non-*IG* promoter. However, *MYC* related oncogenesis is probably not sufficient to explain these differences, and additional genetic and environmental factors probably interact.

In conclusion, our study shows that *MYC*-Ig rearrangements are negative predictors of survival in DLBCL patients in the setting of prospective controlled clinical trials. Because immunostaining for MYC is not a robust approach to prescreen for DLBCL patients with *MYC* breaks, we believe that primary DLBCL patients should be investigated for *MYC* breaks by FISH, at least in the GCB subtype. In addition, *MYC*-R patients should be screened for the *IG MYC* partner gene. We also show that *MYC*-R predicted a worse prognosis with no interaction with treatment arm and chemotherapy regimen suggesting that conventional chemotherapy, such as *R*-CHOP or intensive *R*-ACVBP regimens are not the optimal approaches for these patients, and that potential targeted therapy acting on the *MYC* oncogenesis pathway should be investigated.

Authorship

Contribution: C.C.-B., G.S., C.H., F.J., K.L., J.-P.J., H.T., T.J.M., and P.G. were responsible for the conception and design of the study; C.C.-B., G.S., C.H., F.J., K.L., J.-P.J., H.T., P.C.-D., M.B., J.B., R.D., D.C., M.P., K.B., B.F., C.R., T.P., N.K., F.P., I.N., R.S., T.J.M., and P.G. performed the data analysis and interpretation; C.C.-B., P.G., F.J., and T.J.M. wrote the manuscript; and all authors provided administrative support, provided study materials or patients, collected and assembled data, and approved the final manuscript.

Conflict-of-interest disclosure: C.C.-B. had an advisory role for Celgene and had travel accommodations provided by Celgene. G.S. received honoraria for advisory boards or meetings from Amgen, Celgene, Gilead, Janssen, Mundipharma, and Roche. K.M. had an advisory role for Celgene and received honoraria from Janssen, Roche, and Celgene; travel accommodations were provided by Amgen, Celgene, and Janssen. C.R. had an advisory role for Celgene and Sunesis; received research funding from Celgene and Chugai; had intellectual property interest with Affichem; and had travel accommodations provided by Amgen and Novartis. C.H. received honoraria from Roche, Amgen, Janssen, and Gilead; and had an advisory role for Janssen, Gilead, Takeda, and Roche. I.N. had travel accommodations provided by Affymetrix. F.J. received honoraria from Celgene, Roche, and Janssen. K.L. received honoraria from Astra-Zeneca and Boehringer Ingelheim. H.T. received honoraria from Celgene, Roche, and Janssen; had an advisory role for Takeda; and received research funding from Celgene. T.J.M. received travel accommodations from Amgen, Mundipharma, and Gilead; and had an advisory role for Merck. P.G. had an advisory role for Takeda and had travel accommodations provided by Zenyaku Kogyo. The remaining authors declare no competing financial interests.

Correspondence: Christiane Copie-Bergman, Département de Pathologie Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; e-mail: christiane.copie@hmn.aphp.fr.

References

1. Swerdlow SH. International Agency for Research on Cancer, World Health Organization: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.

2. Dang CV. MYC on the path to cancer. *Cell*. 2012;149(1):22-35.

3. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. *Br J Haematol*. 2010;149(4):484-497.

4. Hummel M, Bentink S, Berger H, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med*. 2006;354(23):2419-2430.

5. Dave SS, Fu K, Wright GW, et al; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med*. 2006;354(23):2431-2442.

6. Klapper W, Stoecklein H, Zeynalova S, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *Leukemia*. 2008;22(12):2226-2229.

7. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. *Histopathology*. 2008;53(2):205-217.

8. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood*. 2009;114(17):3533-3537.

9. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. *J Clin Oncol*. 2010;28(20):3360-3365.

10. Valera A, López-Guillermo A, Cardesa-Salzmann T, et al; Grup per l'Estudi dels Limfomes de Catalunya i Balears (GELCAB). MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Haematologica*. 2013;98(10):1554-1562.

11. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol*. 2012;30(28):3460-3467.

12. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Clin Oncol*. 2012;30(28):3452-3459.

13. Horn H, Ziepert M, Becher C, et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. *Blood*. 2013;121(12):2253-2263.

14. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. *Blood*. 2013;121(20):4021-4031.

15. Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. *Mod Pathol*. 2014;27(7):958-971.

16. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. *Blood*. 2011;117(8):2319-2331.

17. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. *Blood*. 2009;114(11):2273-2279.

18. Foot NJ, Dunn RG, Geoghegan H, Wilkins BS, Neat MJ. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience. *J Clin Pathol*. 2011;64(9):802-808.

19. Pedersen MØ, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. *Eur J Haematol*. 2012;89(1):63-71.

20. Pedersen MØ, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. *Eur J Haematol*. 2014;92(1):42-48.

21. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. *Leukemia.* 2007; 21(3):515-523.

22. Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. *Cancer.* 2012; 118(6):1566-1573.

23. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. *Haematologica.* 2007;92(10): 1335-1342.

24. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. *Mod Pathol.* 2006;19(1): 25-33.

25. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. *Leukemia.* 2009;23(4):777-783.

26. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/ leukemia patients carrying both BCL2 and MYC translocations. *Haematologica.* 2009;94(7): 935-943.

27. Snuderl M, Kolman OK, Chen Y-B, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. *Am J Surg Pathol.* 2010;34(3): 327-340.

28. Kanagal-Shamanna R, Medeiros LJ, Lu G, et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or

MYC gene rearrangements and a poor prognosis. *Histopathology.* 2012;61(5):945-954.

29. Récher C, Coiffier B, Haioun C, et al; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet.* 2011;378(9806):1858-1867.

30. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. *Haematologica.* 2011;96(8):1136-1143.

31. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. *Lancet Oncol.* 2013; 14(6):525-533.

32. Peyrade F, Jardin F, Thieblemont C, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2011;12(5):460-468.

33. Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. *J Clin Oncol.* 2014;32(35):3996-4003.

34. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood.* 2004;103(1):275-282.

35. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. *J Clin Oncol.* 2009;27(33):5573-5579.

36. Martín-Subero JI, Harder L, Gesk S, et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. *Int J Cancer.* 2002;98(3):470-474.

37. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. *Adv Anat Pathol.* 2011;18(3): 219-228.

38. Aukema SM, Kreuz M, Kohler CW, et al; Molecular Mechanisms in Malignant Lymphomas Network Project. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. *Haematologica.* 2014;99(4):726-735.

39. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. *Cancer.* 2012;118(17): 4173-4183.

40. Muñoz-Mármol AM, Sanz C, Tapia G, Marginet R, Ariza A, Mate JL. MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection. *Histopathology.* 2013;63(3): 418-424.

41. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. *J Clin Oncol.* 2011;29(14):1835-1843.

42. Mationg-Kalaw E, Tan LHC, Tay K, et al. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? *Histopathology.* 2012;61(6): 1214-1218.